Accelerated atherosclerosis in autoimmune rheumatic diseases

Abstract

Atherosclerosis is increasingly considered an immune system-mediated process of the vascular system. Autoantibodies, autoantigens, pro-inflammatory cytokines and infectious agents play a role in that process. Autoimmunity-related cardiovascular disease and atherosclerosis are important clinical problems. The reason for accelerated atherosclerosis in patients with autoimmune rheumatic diseases remains unclear. Some cases of autoimmunity-related cardiovascular disease may be more related to thrombosis than atherosclerosis. Although, mechanisms causing the increased risk are not precisely clarified, a combination of traditional and nontraditional risk factors, including inflammation appears to be of importance. Further studies are needed to determine whether these autoimmune rheumatic diseases are also associated with accelerated atherosclerosis and its manifestations.

Keywords

• Atherosclerosis, autoimmune rheumatic diseases, mechanisms

Accelerated atherosclerosis in autoimmune rheumatic diseases

Öz

Ateroskleroz artan bir şekilde dammar sisteminin immune system aracılı bir oluşumu olarak algılanmaktadır. Otoantikorlar, otoantijenler, yangı artırıcı sitokinler ve enfeksiyöz etkenler bu oluşumda rol alabilir. Ototimmunite bağlantılı kalp-damar hastalıkları ve damar sertliği önemli klinik sorunlardır. Otoimmun romatizmal hastalıklarda hızlanmış damar sertliği gelişmesinin nedeni açık değildir. Bazı otoimmunite ilişkili kalp-damar sorunları damar sertliğinden ziyade tromboz ile ilişkilidir. Artan riskin mekanizmaları net olarak açıklanmamakla birlikte, geleneksel olan ve olmayan risk faktörlerinin - yangı da içlerinde olarak – bir kombinasyonu önemli gözükmektedir. Otoimmun romatizmal hastalıkların hızlanmış damar sertleşmesi ve belirtileri ile birlikte olup olmadığı konusunda yeni araştırmalara gereksinim vardır.

Anahtar Kelimeler

• Damar sertliği, otoimmun hastalıklar, mekanizmalar

Kaynakça

1. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoim- mune rheumatic diseases-mechanisms and clinical findings. Clin Rev Allergy Immunol 2009;37:20-8
2. Wick G, Knoflach M, Xu Q. Autoimmune and inflamma- tory mechanisms in atherosclerosis. Annu Rev Immunol 2004;22:361-403
3. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109(Suppl I): II-2-II-10
4. Jara LJ, Medina G, Vera-Lastra G, Amigo MC. Accelerated atherosclerosis, immune response and autoimmune rheu- matic diseases. Autoimmun Rev 2006;5:195-201.
5. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atheroscle- rosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-3347.
6. Shoenfeld Y, Sherer Y, Haratz D. Atherosclerosis as an infec- tious, inflammatory and autoimmune disease. Trends Im- munol 2001;22:293-295.
7. Goodson N. Coronary artery disease and rheumatoid arthri- tis. Curr Opin Rheumatol 2002;14:115-20
8. Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheu- matol 2006;33:2425-2432

9. Van Doornum S, Mc Coll G, Wicks IP. Accelerated athero- sclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-873.
10. Maradit–Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
11. del Rincon I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A. Association between carotid atherosclero- sis and markers of inflammation in rheumatoid arthritis pa- tients and healthy subjects. Arthritis Rheum 2003;48:1833- 40.
12. Gerli R, Schillaci G, Giordano A, et al. CD4+CD28-T lym- phocytes contribute to early atherosclerotic damage in rheu- matoid arthritis patients. Circulation 2004;109:2744-8.
13. Gerli R, Bocci EB, Sherer Y, Vaudo G, Moscatelli S, Shoe- nfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:724-5.
14. Nakken B, Szodoray P. Accelerated atherosclerosis in rheu- matoid arthritis: rational for mannose-binding lectins? J Rheumatol 2010;37:482-4.
15. Frostegand J. SLE, atherosclerosis and cardiovascular dis- ease. J Intern Med 2005;257:485-95
16. Szekanecz Z, Shoenfeld Y. Lupus and cardiovascular dis- ease: the facts. Lupus 2006;15(11_suppl): 3-10.
17. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-93
18. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus . N Engl J Med 2003;349:2399-406
19. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Athero- sclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003;25:79-87.
20. Spronk PE, Overbosch EH, Schut NH. Severe atheroscle- rotic changes, including aortic occlusion, associated with hyperhomocysteinaemia and antiphospholipid antibodies. Ann Rheum Dis 2001;60:699-701.
21. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syn- drome: preliminary data. Ann Rheum Dis 2005;64:315-7.
22. Jimenez S, Garcia-Criado MA, Tassies D, et al. Preclini- cal vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005;44:756-61.
23. Matucci Cerinic M, Fiori G, Grenbaum E, Shoenfeld Y. Macrovascular disease in systemic sclerosis. In: Furst D, Clements P, eds. Systemic sclerosis. Baltimore, Md: Lip- pincott Williams and Wilkins; 2003; 241.
24. Szucs G, Timar O, Szekanecz Z, et al. Endothelial dysfunc- tion precedes atherosclerosis in systemic sclerosis-rele- vance for prevention of vascular complications. Rheuma- tology 2007;46:759-62.
25. Alan S, Ulgen MS, Akdeniz S, Alan B, Toprak N. Intima- media thickness and arterial distensibility in Behçet’s dis- ease. Angiology 2004;55:413-9.
26. Cantu C, Pineda C, Barinagarrementeria F, Salgado P, Gurza A, Paola de P, Espinosa R, Martinez-Lavin M. Noninvasive cerebrovascular assessment of Takayasu arteritis. Stroke 2000;31:2197-202.
27. de Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with We- gener’s granulomatosis. Ann Rheum Dis 2005;64:753-9.
28. Bacon PA. Endothelial cell dysfunction in systemic vas- culitis: New developments and therapeutic prospects. Curr Opin Rheumatol 2005;17:49-55.